Tag - CVKD

Developments

Cadrenal plans RPDD request for tecarfarin in KD

Cadrenal Therapeutics (NASDAQ: CVKD) announced plans to submit a Rare Pediatric Disease Designation (RPDD) request to the FDA for tecarfarin as a treatment for pediatric patients with Kawasaki disease (KD) who develop...

June 18, 2026

Executive Moves

Cadrenal appoints Dr. Lee Golden to BOD

Cadrenal Therapeutics (NASDAQ: CVKD) has announced the appointment of Lee Scott Golden, MD, to its board of directors (BOD) as an independent director, effective immediately. Dr. Golden currently serves as EVP and CMO...

December 1, 2025

Developments

Cadrenal reveals clinical trial plans for tecarfarin in ESKD

Cadrenal Therapeutics (NASDAQ: CVKD) has announced clinical trial initiation plans for its lead late-stage candidate, tecarfarin, for the treatment of patients with end-stage kidney disease (ESKD) transitioning to...

August 5, 2025

Tag - CVKD

Cadrenal plans RPDD request for tecarfarin in KD

Cadrenal appoints Dr. Lee Golden to BOD

Cadrenal reveals clinical trial plans for tecarfarin in ESKD

Subscribe